查看購物車
  • Japanese
  • Korean
青光眼治療市場（2026）：2025年至2031年全球市場分析
市場調查報告書
商品編碼
2026995

青光眼治療市場（2026）：2025年至2031年全球市場分析

2026 Glaucoma Pharmaceuticals Market Report: Global Analysis for 2025 to 2031
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

什麼是新的：

《2026年青光眼治療市場報告》包含了最新的區域青光眼盛行率和診斷率估算、更新的銷售預測，以及對處方模式的更詳細分析，並按美國和西歐的一線治療和輔助性治療治療進行了分類。該報告還提供了美國和日本按藥物類別（學名藥與品牌藥）分類的最新市場佔有率分析，以及公司層面的市場佔有率分析。

在創新方面，該報告擴大了藥物研發管線的範圍，按治療方法對正在進行和正在招募的臨床試驗進行了詳細分析，並納入了對醫生對緩釋製劑滿意度的新見解，從而更清晰地展現了下一代治療方法如何有可能重塑市場。

概述：

《青光眼治療市場（2026）報告》對全球和區域青光眼治療市場進行了數據驅動的分析，重點在於影響未來成長的趨勢和競爭因素。該報告涵蓋了所有主要治療類別直至2031年的預測，包括前列腺素（品牌藥和非專利）、 BETA阻斷劑、碳酸酐酶抑制劑、α促效劑、固定組合藥物、一氧化氮（NO）供體和Rho激酶抑制劑。

此外，本報告檢驗了30 多個有前景的開發平臺，並分析了 23 家主要企業，以深入了解產品系列、策略定位和未來前景。

目錄：

本報告結合當前市場分析和五年預測，全面、數據驅動地展現了全球青光眼治療市場，幫助相關人員了解市場現狀及其至2031年的發展趨勢。報告從市場範圍的八個區域和經濟細分市場對市場進行評估，並對疾病盛行率和治療需求做出一致的預測。此外，報告還提供了重要的臨床和市場背景信息，幫助讀者更深入地了解疾病、患者群體特徵以及不斷發展的治療標準。

適用範圍如下：

  • 青光眼的類型、危險因子和疾病進展
  • 診斷路徑和治療方法
  • 全球青光眼醫療保健提供者（包括眼科醫生和驗光師）的現狀。
  • 目前全球疾病流行情況的估計、預測和 5 年展望。
  • 市售青光眼藥物及其作用機制
  • 學名藥與品牌藥之間的競爭趨勢
  • 對正在研發中的青光眼治療藥物進行管線分析
  • 主要企業及其策略定位概述
簡介目錄

What's New:

The “2026 Glaucoma Pharmaceuticals Market Report” features refreshed estimates of glaucoma prevalence and diagnosis rates by region, along with updated sales forecasts and a more detailed view of prescribing patterns—now stratified by first-line and adjunctive use in the US and Western Europe. The report also delivers updated market share analysis by drug class (generic vs. proprietary) in the US and Japan, as well as company-level share insights.

On the innovation side, expanded coverage of the pharmaceutical pipeline includes a deeper look at active and recruiting clinical trials by therapy type, along with new insight into physician satisfaction with extended drug-release devices to provide a clearer view of how next-generation treatments may reshape the market.

Description:

The “2026 Glaucoma Pharmaceuticals Market Report” provides a data-driven view of the global and regional glaucoma drug markets, highlighting the trends and competitive forces shaping future growth. The report includes forecasts through 2031 across all major therapy classes, including prostaglandins (branded and generic), beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combinations, NO-donating compounds, and Rho-kinase inhibitors.

In addition, the report examines a robust development pipeline of over 30 drug candidates and profiles 23 leading companies, providing insight into product portfolios, strategic positioning, and future outlook.

Contents:

This report delivers a comprehensive, data-driven view of the global glaucoma pharmaceuticals market, combining current market analysis with five-year forecasts to help stakeholders understand where the market stands today and where it is headed by 2031. Markets are evaluated across Market Scope’s eight regional/economic categories, with aligned forecasts for disease prevalence and treatment demand. The report also provides essential clinical and market context, offering a deeper understanding of the disease, patient populations, and evolving standards of care.

Coverage includes:

  • Glaucoma types, risk factors, and disease progression
  • Diagnosis pathways and treatment approaches
  • Global landscape of glaucoma care providers, including ophthalmologists and optometrists
  • Current estimates and five-year forecasts for worldwide disease prevalence
  • Marketed glaucoma drugs and their mechanisms of action
  • Competitive dynamics between generic and branded therapies
  • Pipeline analysis of emerging glaucoma pharmaceuticals
  • Profiles of leading companies and their strategic positioning